India revises foreign direct investment rules to bridle any attempts at opportunistic M&A amid the COVID-19 crisis. The move is seen largely targeted at China, though pharma experts have mixed views on the new screening measures.
India has tweaked its foreign direct investment (FDI) rules, amid concerns that unprecedented stress as a result of the coronavirus pandemic could expose domestic firms across sectors to opportunistic takeovers and acquisitions.
The new norms, widely seen as targeted mainly at China, essentially require nations that border India to secure government approval prior to investing in India in sectors where such investment...
As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.
India is pressing ahead with “big shifts” in its regulatory approach for cell and gene therapies. Reduced “layers of review”, tighter internal timelines, upcoming guidelines to facilitate CGT development and reforms in the constitution of expert committees are some of the key changes.
US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
